Search

Your search keyword '"Gertig, D."' showing total 134 results

Search Constraints

Start Over You searched for: Author "Gertig, D." Remove constraint Author: "Gertig, D."
134 results on '"Gertig, D."'

Search Results

1. Prognostic gene expression signature for high-grade serous ovarian cancer

2. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

3. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

4. Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.

5. Prognostic gene expression signature for high-grade serous ovarian cancer

6. Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.

7. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

8. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study

10. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

11. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium

12. Spatial variation in cervical cancer screening participation and outcomes among Indigenous and non-Indigenous Australians in Queensland

14. BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition.

15. Spatial variation in cervical cancer screening participation and outcomes among Indigenous and non-Indigenous Australians in Queensland

16. Management and long-term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study

19. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

20. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

21. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial

22. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial

23. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53mutation status in ovarian mucinous tumors: implications for outcome analyses

24. Annexin A1 expression in a pooled breast cancer series: Association with tumor subtypes and prognosis

25. The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011)

26. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use

27. Progesterone Receptor Promoter +331A Polymorphism is Associated with a Reduced Risk of Endometrioid and Clear Cell Ovarian Cancers

28. Fine-scale mapping of the 4q24 locus identifies & pr two Independent loci associated with breast cancer risk

29. Annexin A1 expression in a pooled breast cancer series: Association with tumor subtypes and prognosis

30. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

31. Improving chlamydia knowledge should lead to increased chlamydia testing among Australian general practitioners: A cross-sectional study of chlamydia testing uptake in general practice

32. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium

34. Skewed X chromosome inactivation and breast and ovarian cancer status: Evidence for X-linked modifiers of BRCA1.

35. Expenditure and resource utilisation for cervical screening in Australia

36. HFE C282Tyr homozygotes with serum ferritin concentrations below 100ug/L are at low risk of hemochromatosis

37. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer

38. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.

39. A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis

40. HFE C282Y/H63D Compound Heterozygotes Are at Low Risk of Hemochromatosis-Related Morbidity

41. Body size and risk of epithelial ovarian and related cancers: A population-based case-control study.

42. Recreational physical activity and epithelial ovarian cancer: A case-control study, systematic review, and meta-analysis.

43. Consortium analysis of 7 candidate SNPs for ovarian cancer.

44. Iron-overload-related disease in HFE hereditary hemochromatosis

45. The Natural History of Serum Iron Indices for HFE C282Y Homozygosity Associated With Hereditary Hemochromatosis

48. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.

49. Genome-wide association study identifies novel breast cancer susceptibility loci.

50. A national surveillance system for newly acquired HIV infection in Australia. National HIV Surveillance Committee

Catalog

Books, media, physical & digital resources